Player Avatar whoodatstockhot (77.36) Submitted: 1/16/2013 2:44:47 PM : Outperform Start Price: $19.52 MELA Score: -12.96

MELA has developed a state of the art device in detecting early stage melanoma, and is a significant improvement over current methods-- the eyes-- which will reduce unnecessary biopies. The product is FDA approved, and has sold off primarily due to tax sellling and significant manipulation by short-sellers. Valuation absurdly cheap. Stock could easily break $3.00 as distribution, sales, and marketing increase in first six months of 2013. Easy buyout candidate in the $8-$10 dollar range.

Featured Broker Partners